Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927055 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
A Phase 3 study, sponsored by Chelsea Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT01927055: Clinical Trial Phase 3 study, sponsored by Chelsea Therapeutics.
NCT01927055 is a Phase 3 study that was terminated before completion, run by Chelsea Therapeutics. The registered enrollment target is 61 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927055, a Phase 3 study, was terminated before completion, sponsored by Chelsea Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
Primary Outcome
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A positive score indicates worsening during the double-blind randomized phase relative to value at randomization, while a negative score indicates an improvement in symptom severity.
Interventions
- DRUG Placebo
- DRUG Droxidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Why NCT01927055 stopped before completion
NCT01927055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01927055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01927055 about?
NCT01927055 is a clinical study titled "A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy". Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
What is the current status of trial NCT01927055?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2013-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01927055?
The interventions under investigation include: Placebo (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT01927055?
This trial is sponsored by Chelsea Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01927055's enrollment target sits among peer trials
61 1803rd of 2000 higher than 197 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia